Takeda’s Phase 4 VERDICT trial has produced the first prospective, randomised evidence that disease clearance is an achievable and clinically relevant treatment target in ulcerative colitis. Patients treated with intravenous Entyvio (vedolizumab) to a corticosteroid free disease clearance target, meaning symptomatic, endoscopic and histologic remission combined, had a significantly longer time to a first ulcerative colitis related complication than patients treated to symptomatic remission alone: hazard ratio 0.33 (95 percent confidence interval 0.17 to 0.67; p=0.0014), a risk reduction of nearly 70 percent, measured up to 80 weeks after target achievement.
The trial randomised 672 adults with moderate to severe ulcerative colitis, most of them bio naive, to three increasingly stringent corticosteroid free targets, with treatment escalated on Entyvio based algorithms, including dose frequency increases, until the assigned target was met. Nearly 60 percent (400 of 672) achieved their assigned target by week 48: 74.1 percent in the symptomatic remission group, 56.3 percent in the symptomatic plus endoscopic group, and 52.1 percent in the disease clearance group. Among patients who hit their target, more than half reached disease clearance by week 16. Fifty one complications occurred in total, with use of rescue therapy the most frequent.
Two qualifications matter. Time to complication was similar between the middle group (symptomatic plus endoscopic remission) and the disease clearance group (hazard ratio 1.10, p=0.8023), so the trial does not show that the histologic layer adds benefit over endoscopic healing; it shows the stringent targets beat symptoms alone. And the primary analysis covers patients who achieved their targets, not all randomised patients, which is the standard treat to target framing but a selected population.
Safety did not price the strategy out. Adverse event rates were similar across groups and unaffected by treatment escalation and more frequent dosing, and the 96 week safety profile was consistent with Entyvio’s known data with no new signals. For Takeda, the commercial read is direct: VERDICT, presented at UEG Week in Barcelona and published in the United European Gastroenterology Journal, gives its gut selective incumbent a disease modification argument on the same morning Gilead reported Phase 2 data for an oral drug built on the same alpha4beta7 mechanism.